Eating Disorder

Alto Neuroscience Inc. has initiated a phase 2 study to determine the safety, tolerability and pharmacokinetics of ALTO-203 among patients with major depressive disorder and to evaluate its effectiveness as an antidepressant.

Axsome Therapeutics has initiated a phase 3 trial of solriamfetol to assess its safety and efficacy for the treatment of binge-eating disorder among adults, according to a company press release.

This year, Eating Disorders Awareness Week is being held from Feb. 26 to March 4.

Children who experienced food-induced anaphylaxis before age 3 years had greater odds for developing eating and sleeping disorders that could persist into adulthood, according to a study published in Pediatric Allergy and Immunology.

Anorexia nervosa during pregnancy was associated with several adverse neonatal outcomes, such as preterm and small for gestational age birth, compared with women without eating disorders, researchers reported.

Hospitalizations for eating disorders have increased steadily among adolescents in the United States, including a spike during the COVID-19 pandemic, researchers reported in Hospital Pediatrics.

Primary care providers are on the front lines of diagnosing and treating anorexia nervosa — a particularly complex eating disorder, according to experts.

Disordered eating behaviors were reported by 42.5% of adolescents with type 1 diabetes who currently use or previously used an insulin pump, according to findings published in Diabetes Technology & Therapeutics.

Eating disorder claims in the United States rose 65% as a percentage of all medical claims over the last 5 years, according to a report from FAIR Health, a health care claims repository.

Both victims and perpetrators of cyberbullying are more likely than other youths to experience eating disorder symptoms, according to study findings published in the International Journal of Eating Disorders.